Bharat Biotech has already eliminated dependency on US imports needed for COVAXIN, that has an 81% efficacy, a 99.9% success rate against post-vaccination CoVID, and is equally effective against B.1.617 mutant.
— Anand Ranganathan (@ARanganathan72) April 24, 2021
America, if YOU need our help, let us know.https://t.co/hM2pKQrUDp